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Abstract 
African sleeping sickness (SS) is a severe, potentially lethal parasitic disease. The treatments 
of choice are the antiparasitic agents suramin, which is adrenotoxic, and/or melarsoprol. We 
evaluated the functional integrity of the hypothalamic-pituitary-adrenal (HPA) axis of 
patients with SS before, during, and after therapy with suramin and/or melarsoprol, in two 
sequential stages. First, we employed the Standard adrenocorticotropic hormone (ACTH) 
1-24 Stimulation test (250 ug i.v.) to assess the maximal adrenocortical responsiveness of 69 
patients with SS and 38 normal controls. We demonstrated paradoxically subnormal cortisol 
responses before suramin therapy [net cortisol response 60 min after Stimulation: 10.5 ± 2.9 
(mean ± SE) vs. 17.5 ± 1.0 ug/dl for controls, p = 0.004], with 27% of the patients falling 
within the adrenal insufficiency ränge (stimulated cortisol concentration <20 ug/dl). These 
responses subsequently and unexpectedly improved with suramin and/or melarsoprol thera-
py. Second, we performed a human corticotropin-releasing hormone (hCRH) test (100 ug 
i.v.) in 68 additional patients with SS and 14 control subjects to examine whether the gluco-
corticoid deficiency observed was primary and/or secondary. Compared to controls, the 
ACTH and cortisol responses to hCRH were blunted (ACTH after 60 min: 29 ± 7 vs. 58 ± 
8 pg/ml in controls, p = 0.014; cortisol: 15.2 ± 1.5 vs. 19.6 ± 0.7 ug/dl, p = 0.018), suggesting 
the presence of secondary adrenal insufficiency. There was improvement of both ACTH and 
cortisol responsiveness to hCRH with therapy, with cortisol recovery occurring before 
ACTH, suggesting an additional primary component of adrenal dysfunction in these patients. 
Plasma concentrations of tumor necrosis factor (TNF)-a (16.0 ± 4.1 vs. 2.9 ± 1.4 pg/ml in 
controls, p = 0.003) and interleukin (IL)-6 (19.2 ± 7.3 vs. 1.3 ± 0.2 pg/ml, p = 0.0001), but 
not IL-lß (2.0 ± 0.2 vs. 0.9 ± 0.2, p = NS), were elevated when adrenocrotical function 
impairment and disease activity were at their maximum, but gradually decreased into the 
normal ränge with therapy. We found a negative correlation between baseline cytokine con-
centrations and maximal cortisol concentrations during hCRH testing (TNF-a: r = -0.31, p = 
0.003; IL-6: r = -0.34, p = 0.002). We conclude that unmedicated SS is associated with signif-
icant impairment of adrenocortical function which is reversed with suramin and/or melarso-
prol therapy in the majority of patients. This impairment may be due to the elevated plasma 
cytokine concentrations, and may represent a natural adaptation of the HPA axis in inflam-
matory states. A controlled therapeutic trial is necessary to demonstrate whether supplemen-
tal glucocorticoids could be beneficial in SS. 
Received: Martin Reincke, MD 
July 26, 1993 Medizinische Universitätsklinik Würzburg 
Accepted: Josef-Schneider-Strasse 2 
August 11,1993 D-97080 Würzburg (FRG) 
Introduction 
Sleeping sickness (SS; African trypanosomiasis) is an 
anthropozoonosis transmitted cyclically by the bite of the 
tsetse fly of the genus G l o s s i n a . It is caused by the proto-
zoans T r y p a n o s o m a b r u c e i gambiense (West-African SS 
with a more chronic course) or T.b. rhodesiense (East-
African SS with rapid progression). Fifty million Africans 
are living in areas where SS is endemic, of which only 10 
million have access to health Services capable of diagnos-
ing trypanosomiasis [1]. Approximately 20,000 new cases 
are reported each year to the World Health Organization, 
although there is considerable fluctuation in number due 
to epidemics [2]. Clinically, the early acute disease is char-
acterized by hemolymphatic involvement with irregulär 
fever, rash, weight loss, localized edema, lymphadenopa-
thy and chronic fatigue, which can last from months to 
years in West-African SS, but has a more acute onset and 
rapid progression in East-African SS. After invasion of the 
central nervous System by the parasite, a meningoen-
cephalitis with a broad spectrum of neurologic and Psy-
chiatric Symptoms evolves. Untreated, the disease is fatal 
and death is due to secondary bacterial infection, coma, 
or cachexia[3,4]. 
Severe illnesses or stress of any kind are usually accom-
panied by activation of the hypothalamic-pituitary-adre-
nal (HPA) axis [5-8] and the sympathetic nervous System 
[9, 10]. The activation of the HPA axis in the course of 
inflammatory disease has been considered to be a result of 
elevated inflammatory cytokine levels, such as those of 
tumor necrosis factor (TNF)-a, interleukin (IL)-lß, and 
IL-6, which have corticotropin-releasing hormone 
(CRH)-, adrenocorticotropin hormone (ACTH)- and/or 
cortisol-releasing properties [for a review see ref. 11]. In 
turn, and primarily via glucocorticoids, the H P A axis 
exerts major anti-inflammatory and immunosuppressive 
effects, thus, participating in the natural control of inflam-
mation [12]. In addition, via C R H and Opioid peptider-
gic-mediated, as well as through glucocorticoid-mediated 
mechanisms, the HPA axis suppresses appetite, induces 
catabolism and inhibits thyroid and gonadal function 
[11]. The presence of cachexia associated with chronic 
parasitic disease has been explained both as a result of 
activation of the HPA axis and sympathetic nervous Sys-
tem and as a consequence of circulating cytokines, such as 
TNF-a (or cachexin), with cachexia-promoting properties 
[13]. 
Endocrine abnormalities in African SS have been ob-
served since the early 1950s and include hypothyroidism, 
and hypogonadism [14-18]. Sporadic cases of adrenal 
insufficiency have also been reported in SS [19], but the 
HPA axis has not been systematically evaluated in this 
condition. Suramin, used since the early 1920s as the 
treatment of choice for SS in the hemolymphatic stage 
[20], eures SS, and corrects the known endocrine and met-
abolic manifestations. This drug, given in large doses to 
patients with AIDS or to macaque monkeys, has signifi-
cant adrenotoxicity and results in adrenocortical insuffi-
ciency [21-23]. To investigate the H P A axis in African SS 
and the potential effects of suramin treatment on this 
axis, we studied cross-sectionally 137 patients with SS and 
52 normal Ugandan controls by means of A C T H 1-24 and 
human (h)CRH Stimulation tests. Unmedicated SS was 
associated with impairment of HPA axis function, despite 
high plasma cytokine concentrations. Paradoxically, H P A 
axis function was corrected by specific treatment with 
suramin and/or melarsoprol in the majority of the pa-
tients. 
Patients and Methods 
Patients and Controls 
Patients and controls were recruited through the National Sleep-
ing Sickness Control Program in south-east Uganda. The diagnosis of 
SS was established by microscopical demonstration of parasites in 
the peripheral blood (hemolymphatic stage), and/or in cerebrospinal 
fluid obtained by lumbar puneture (cerebral stage). All patients with 
SS initially reeeived a small i.v. dosage of suramin (day 1:250 ug, day 
3: 500 ug). Thereafter, patients without cerebral involvement (hemo-
lymphatic stage) reeeived weekly 1-gram injections of suramin up to 
a total dose of 5.75 g, whereas patients with cerebral SS were treated 
with a 5-week course of melarsoprol (total dose: 20 mg/kg body 
weight). 
A total of 137 patients (67 female, 70 male; mean age 36 years) 
with T.b. rhodesiense infection and 52 healthy Ugandan control sub-
jects (24 female, 28 male; mean age 30 years) were enrolled in two 
different sequential protocols (1 and 2, see below), after giving 
informed consent. None of the healthy subjects had a previous histo-
ry of SS, adrenal disease or had reeeived suramin, melarsoprol, or 
glucocortieoid treatment. Every patient was studied during the 
course of treatment (1) while acutely ill, within the first 5 days after 
admission to the health care center; (2) in the middle of the course of 
treatment (days 8-21); (3) at the end of the treatment period (days 
23-38), and (4) after permanent eure (at least 3 months after the end 
of treatment). 
The study was approved by the ethics committee of the Universi-
ty of Cologne and by the Ministry of Health, Uganda, and post hoc by 
the ICRS oftheNICHD. 
Protocol 1 
Sixty-nine patients and 38 controls underwent an ACTH Stimula-
tion test between 10.00 and 14.00. The clinical profile of these 
patients is given in table 1. 250 ug ACTH 1-24 (Synacthen®, Ciba-
Geigy, Wehr, FRG) was given as an i.v. bolus. Venous blood was 
15 
Table 1. Clinical profile of patients and controls studied with ACTH 1-24 
n Sex Hemo- Cerebral Mean agea Mean time of 
(f/m) lymphatic stage test after onset 
stage of therapya 
Normal controls 38 17/21 _ _ 28(18-42) _ 
Patients shortly after admission 11 5/6 7 4 34(19-60) 2.4(1-4) days 
Patients after 2 weeks of treatment 22 11/11 12 10 34(19-60) 13.3(9-18) days 
Patients after 4 weeks of treatment 22 9/13 14 8 35 (18-65) 29.5 (23-33) days 
Patients after eure 14 9/5 10 4 44(18-65) 7(0.3-14) years 
The ränge is given in parentheses. 
Table 2. Clinical profile of patients and controls studied with hCRH 
n Sex Hemo- Cerebral Mean agea Mean time of 
(f/m) lymphatic stage years test after onset 
stage of therapy3 
Normal controls 14 7/7 _ _ 34(21-60) _ 
Patients shortly after admission 15 5/10 6 9 34 (20-60) 3.6 (2-5) days 
Patients after 2 weeks of therapy 19 10/9 9 10 36 (21-56) 14.4 (8-21) days 
Patients after 4 weeks of therapy 20 11/9 11 9 38(18-65) 29.9 (23-38) days 
Patients after eure 14 7/7 6 8 39 (20-66) 25 (9-43) months 
a The ränge is given in parentheses. 
drawn at 0 and 60 min for determination of serum cortisol. Serum 
suramin concentrations were measured in the baseline samples. 
The samples were stored on ice for up to 6 h, then centrifuged and 
stored at -20 °C. After transportation to the FRG or USA on dry ice, 
all samples from a Single patient were run in the same assay. 
Protocol 2 
Sixty-eight patients with SS and 14 normal subjects had a hCRH 
Stimulation test between 10.00 and 14.00. The clinical profile of 
these patients is given in table 2. After placing an indwelling catheter 
in the antecubital vein, blood was drawn for determination of plasma 
ACTH and serum cortisol at baseline and 15, 30 and 60 min after a 
bolus injection of 100 ug hCRH i.v. (Corticobiss, Bissendorf GmbH, 
Hannover, FRG). The concentrations of TNF-a, IL-1 ß and 11^ 6 were 
determined in the baseline plasma samples. The samples were imme-
diately chilled at 4°C, centrifuged and stored at -20 °C. 
Assays 
Plasma ACTH was determined in duplicate by a commercial two-
site immunoradiometric assay (Nichols, Bad Nauheim, FRG). The 
interassay and intraassay variability were 7.3 and 2.6%, respectively. 
Serum cortisol (Serono, Freiburg, FRG) was determined by specific 
RIA with commercial reagents. The inter- and intra-assay variability 
were 5.1 and 2.2%, respectively. Serum suramin concentrations were 
determined by HPLC in a modification of the method of Klecker and 
Collins [24]. TNF-a, IL-lß and IL-6 were determined by specific 
ELISA using commercial assays (R & D Systems, Minneapolis, 
Minn., USA). The lower limits of detection of these assays were, 2.8, 
1.0 and 1.0 pg/ml, respectively, and the inter- and intra-assay vari-
ability 6.4 and 7.8, 3.0 and 5.0, and 7.8 and 7.5%, respectively. 
Statistics 
The data of patients with hemolymphatic and cerebral SS were 
analyzed separately, to exclude effects of disease stage and treatment 
on the HPA axis. Since no significant differences were found, the 
combined data of both groups are shown. All data are expressed as 
mean ± SEM, if not otherwise stated. The normal ränge of hormones 
and peptides was defined as the mean of the controls ± 2 SD. The 
total integrated ACTH and cortisol responses to hCRH were calcu-
lated by the trapezoid method and expressed as area under the hor-
mone concentration time curve (AUC) from 0 to 60 min. The net 
integrated ACTH and cortisol responses to hCRH were expressed as 
the AUC from 0 to 60 min minus the area generated by the baseline 
value multiplied by 60 min. Differences between group means were 
assessed using a nonparametric one-way ANOVA (Kruskal-Wallis 
test) and the Mann-Whitney U test for unpaired data, as appropriate. 
Correlations were examined with linear-regression analysis after log-
arithmic transformation of cytokine concentrations and expressed as 
Pearson's correlation coefficient. A p < 0.05 was considered statisti-
cally significant. 
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Results 
A C T H S t i m u l a t i o n Test 
Sixty-nine patients with SS and 39 age- and sex-
matched normal Ugandan controls underwent an A C T H 
Stimulation test to assess the maximum cortisol secretory 
capacity of the adrenal cortex (fig. 1). Compared to nor-
mal controls, total and net A C T H 1-24-stimulated corti-
sol concentrations were significantly lower in patients 
with SS than in controls (Kruskal-Wallis test: p = 0.0001 
and 0.0009, respectively). Shortly after onset of therapy, 
SS patients had low total A C T H 1-24-stimulated cortisol 
concentrations (26.8 ± 3.2 vs. 33.0 ± 1.0 jig/dl, p = 0.01) 
and a subnormal net cortisol response (10.5 ± 2.9 vs. 17.4 
± 1.0 u-g/dl, p = 0.004). After 2 and 4 weeks of treatment, 
which resulted in marked clinical improvement, stimulat-
ed cortisol concentrations in the patients were subnormal, 
whereas the net cortisol responses were still significantly 
lower than in controls (11.7 ± 1.1 jag/dl after 2 weeks of 
treatment, p = 0.0005 vs. controls; 13.2 ± 0.7 jxg/dl after 
4 weeks of treatment, p = 0.0004). After eure, adrenocorti-
cal function improved somewhat, but not completely. 
Maximal circulating cortisol concentrations after A C T H 
1-24 Stimulation were significantly lower than in controls 
(25.6 ± 1.4 |ig/dl, p = 0.006); however, the mean cortisol 
increase in these patients was normal (15.0 ± 1.7 jig/dl 
vs. 17.4 ± 1.0jxg/dl,p = 0.5). 
Three of 11 (27%) patients on admission, 4 of 22 (18%) 
after 2 weeks of treatment, 6 of 22 (27%) after 4 weeks of 
treatment and 2 of 14 (14%) patients after eure had stimu-
lated cortisol concentrations below the conventionally 
aeeepted level of 20 jug/dl [25]. 
Serum suramin concentrations in patients with SS 
ranged from 9.0 to 135.4 jig/ml and correlated well with 
the individual dose given to the patient. Mean suramin 
levels increased gradually during the course of suramin 
treatment in patients with hemolymphatic SS, but re-
mained low in patients with cerebral SS on melarsoprol 
therapy, who reeeived only the initial suramin dose of 
0.75 g. Al l patients reeeiving suramin had therapeutic lev-
els above 50 jug/ml at the end of the treatment period. 
After eure, 5 patients had still measurable suramin levels 
(the half-life of suramin in plasma is approximately 50 
days), whereas in the remaining patients the levels were 
under the limit of detection (<1.5 jig/ml). No correlation 
was found between suramin concentrations and the maxi-
mal cortisol concentrations (r = 0.13) or the net cortisol 
response (r = 0.005) after A C T H Stimulation. 
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CORTISOL INCREASE 
Ü 20 
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• P<0.005 
t P<0.0005 
Fig. 1. A Serum cortisol concentrations 60 min after i.v. adminis-
tration of 250 jug of ACTH 1-24 in 69 African patients with SS and 38 
age- and sex-matched controls studied in parallel. Controls (CON), 
newly admitted, unmedicated patients (ADM), after 2 (2 WKS) and 
4 (4 WKS) weeks of suramin and /or melarsoprol treatment, and after 
eure. The means of each group are depicted as horizontal lines. 
Patients were significantly different from controls: ADM, p = 0.007; 
2 WKS, p = 0.0001; 4 WKS, p = 0.0001; CURE, p = 0.006). The 
interrupted Line represents the conventionally aeeepted minimal nor-
mal cortisol concentration after ACTH Stimulation [25]. B Mean 
( ± SE) serum cortisol increases in controls and patients with SS: 
Patients were significantly different from controls, as indicated. 
h C R H - S t i m u l a t i o n Test 
Sixty-eight patients with SS and 14 Ugandan age- and 
sex-matched control subjects underwent a hCRH Stimula-
tion test (fig. 2). Baseline A C T H and cortisol concentra-
tions did not differ significantly between patients with SS 
and control subjects (Kruskal-Wallis test: p > 0.05 for 
A C T H , p = 0.4 for cortisol). Although severely il l , patients 
studied shortly after admission showed no stress-induced 
activation of the HPA axis (baseline A C T H : 24 ± 5 vs. 24 
± 5 pg/ml in controls; cortisol: 12.5 ± 1.1 vs. 11.2 ± 
0.7 u.g/dl). 
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Fig. 2. Mean ( ± SE) baseline and hCRH-stimulated (100 jug i.v.) plasma ACTH (upper panel) and serum cortisol 
(lower panel) concentrations in African patients with SS and age- and sex-matched controls studied in parallel. The 
Symbols denote significant changes between patients (PA) and controls (CO). 
After Stimulation with hCRH, the A C T H response was 
blunted in patients with SS (Kruskal-Wallis test for 
A C T H at 30 and 60 min: p = 0.01 and 0.005, respective-
ly). A C T H concentrations in untreated patients were low 
compared to controls after 60 min (29 ± 7 vs. 58 ± 8 pg/ 
ml, p = 0.014). In addition, the net integrated A C T H 
increase was reduced in the patients (1,131 ± 289 vs. 
2,149 ± 357 pg/ml x min; p = 0.045). The subnormal 
A C T H response to hCRH was even more pronounced 
after 2 and 4 weeks of treatment, but was not different 
from controls after permanent eure (fig. 2). 
The cortisol response to hCRH was also subnormal 
(Kruskal-Wallis test for maximum cortisol increase: p = 
0.006). Patients studied shortly after admission had low 
cortisol concentrations after 60 min (15.2 ± 1.5 vs. 19.6 
± 0.7 |ig/dl in controls, p = 0.018), a low net integrated 
cortisol increase (182 ± 46 vs. 377 ± 36 jag/dl x min, p = 
0.035) and a significantly reduced maximum cortisol 
increase (4.4 ± 1.1 vs. 9.36 ± 0.7 jug/dl, p = 0.0012). 
After 2 and 4 weeks of treatment, a normalization of the 
cortisol response to h C R H was observed, despite subnor-
mal levels of the corresponding A C T H concentrations. 
After permanent eure, the cortisol response to hCRH was 
normal. 
Defining the normal response intervals to hCRH as the 
peak cortisol concentration of the controls ± 2 SD (15.3-
25.7 jig/dl), 50% of the patients at admission, 37 and 15% 
after 2 and 4 weeks of treatment, respectively, and 14% 
afte eure of SS had a subnormal cortisol response. 
C y t o k i n e s 
In patients undergoing hCRH Stimulation, basal circu-
lating TNF-a, IL-lß and IL-6 concentrations were deter-
mined (fig. 3A). TNF-a (Kruskal-Wallis test, p = 0.005) 
and IL-6 (Kruskal-Wallist test, p = 0.0001), but not IL-lß, 
were substantially elevated in SS. TNF-a concentrations 
were high in patients shortly after admission (16.0 ± 4.5 
vs. 2.9 ± 1.4 pg/ml in controls, p = 0.003) and returned to 
normal after 2 and 4 weeks of treatment (3.8 ± 1.6 and 
6.5 ± 1.7 pg/ml, respectively). A weak but significant 
inverse correlation was observed between basal TNF-a 
concentrations and peak cortisol concentrations after 
hCRH Stimulation (r = -0.31, p = 0.003; fig. 3B). IL-lß 
concentrations were undetectable in most of the patients 
with SS, and mean immunoreactive concentrations did 
not differ from control subjects (0.9 ± 0.2 vs. 2.0 ± 
0.8 pg/ml, p = NS), IL-6 concentrations, on the other 
hand, were dramatically elevated in SS (19.2 ± 7.3 vs. 2.9 
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Fig. 3. A Mean ( ± SE) plasma cytokine concentrations in controls (CON) and newly admitted, unmedicated SS 
patients (ADM), after 2 (2 WKS) and 4 weeks (4 WKS) of treatment, and after eure (CURE). * p = 0.02, ** p = 0.003, 
*** p = 0.0001, patients vs. controls (Mann-Whitney U test). B Correlation between maximal serum cortisol concen-
trations during the hCRH test and baseline TNF-a (upper graph) and IL-6 concentrations (lower graph) in patients 
with SS and controls. 
± 1.4 pg/ml in controls, p = 0.0001) and slowly returned 
to normal (after 2 weeks: 16.3 ± 10.8 pg/ml; after 4 
weeks: 2.8 ± 1.6 pg/ml). Peak cortisol concentrations 
after h C R H Stimulation were negatively correlated with 
basal IL-6 concentrations (r = -0.34, p = 0.002; fig. 3B). 
Discussion 
African trypanosomiasis is associated with extensive 
mononuclear infiltration of organs penetrated by the par-
asite [26, 27]. Numerous complications of SS have been 
described, including pancarditis, glomerulonephritis, 
hepatitis, autoimmune thrombocytopenia, acquired cellu-
lar and humoral immunodeficiency, hypothyroidism and 
hypogonadism [3, 4, 15-18]. Based on the present Und-
ings, we add a new frequent complication to this list: 
impairment of adrenocortical function. In our study, pa-
tients with SS as a group had a subnormal cortisol 
response to A C T H 1-24 and a blunted A C T H and cortisol 
response to hCRH. These alterations in the H P A axis 
were almost completely reversed with suramin and/or 
melarsoprol treatment. 
By Standard biochemical criteria, the hypocortisolism 
observed in SS appears to be mild to moderate. Baseline 
A C T H and cortisol concentrations were in the normal 
ränge, and cortisol concentrations after A C T H 1-24 were 
above 10 |ig/dl, with one third of the patients below the 
conventional criterion of 20 jig/dl [25]. However, one 
could argue for a clinically relevant glucocortieoid deficit 
in this condition, even in patients with peak cortisol con-
centrations exceeding 20 jig/dl. Patients with untreated 
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SS are exposed to severe disease-related stress and should 
have an activation of the HPA axis analogous to the 
severity of their disease [5-8]. 'Normal' baseline A C T H 
and cortisol concentrations in these patients and lack of 
increased responsiveness to A C T H 1-24 may, thus, re-
flect a relative glucocorticoid deficit, which may require 
glucocorticoid replacement therapy. Interestingly, high-
dose glucocorticoids have been successfully used as an 
adjunctive therapy for cerebral SS in uncontrolled stud-
ies [4]. The reduced morbidity and mortality seen with 
this regimen may be attributed not only to the suppres-
sive effects of glucocorticoids on the inflammatory reac-
tion within the CNS, but also to other beneficial effects 
of appropriate glucocorticoid replacement in these pa-
tients, such as prevention of hypotension or a frank adre-
nal crisis. 
What is the locus of the functional defect of the HPA 
axis in SS? Our results favor a combined (central and 
peripheral) origin of dysfunction. The low A C T H re-
sponse to hCRH before and after 2 and 4 weeks of treat-
ment seems to favor a secondary adrenocortical insuffi-
ciency. However, the cortisol response to h C R H was 
improved at 2 and 4 weeks, despite concurrently low 
A C T H concentrations, arguing for an independent prima-
ry adrenocortical dysfunction which resolved earlier than 
the pituitary A C T H deficiency. The combined nature of 
adrenal insufficiency in patients with SS is reminiscent of 
the hypothyroidism and hypogonadism observed in this 
disease, which also simultaneously involve the hypotha-
lamic-pituitary unit and the gonads [15-18, 28-32]. 
Suramin has been shown to have adrenotoxic proper-
ties in vivo [21-23] and in vitro (33, 34). Primary adreno-
cortical insufficiency was induced in patients with AIDS 
after 2-6 months treatment with a cumulative dosage of 
more than 10 g suramin [21, 22]. Suramin concentrations 
in these patients were invariably higher than 150 ug/ml, 
and often higher than 250 ug/ml. Because of the toxic 
effects of suramin on the adrenal cortex, it has been used 
as an antitumor drug in primary adrenocortical Carcino-
ma [33, 34]. Generally, at this time, patients undergoing 
suramin treatment are routinely considered at risk for pri-
mary adrenal failure and receive concurrent glucocorti-
coid replacement therapy [33]. Surprisingly, we observed 
no case of suramin-induced adrenal insufficiency in our 
patients with SS and, paradoxically, we observed im-
provement of adrenocortical function with therapy. No 
correlation was found between the peak cortisol levels 
after A C T H and the basal serum suramin levels. These 
results may be explained by the lower cumulative dose of 
suramin given to our patients (maximum 5.75 g), by the 
shorter duration of suramin administration, and/or by the 
lower serum suramin levels achieved compared to pa-
tients with AIDS or Cancer patients. 
The pathogenesis of the impairment of the pituitary 
and adrenocortical function that we observed in SS is not 
clear. It could be explained in two major ways, which are 
not mutually exclusive. First, it may be due to parasite 
infiltration and transient inflammatory dysfunction of the 
pituitary and/or adrenal cortices. Animal and human data 
support this possibility [8,27, 30-32]. Hence, experimen-
tal infection with T. b r u c e i in sheep, resulted in acute co-
agulative necrosis of the adenohypophysis and leukocytic 
infiltration of the neurohypophysis, with trypanosomas 
present in pituitary tissue [35]. In humans, on the other 
hand, pituitary fibrosis with panhypopituitarism, includ-
ing adrenal insufficiency, was reported in 2 patients with 
SS [19]. In both of these paradigms, however, the adrenal 
insufficiency was severe and permanent, in contrast to the 
mild to moderate transient dysfunction that we observed. 
Second, although the inflammatory cytokines TNF-a, IL-
1 ß and IL-6 administered acutely stimulate C R H , A C T H 
and/or cortisol release [36-39], chronic exposure to high 
endogenous cytokine levels may be associated with sup-
pression of H P A axis activity. The high circulating TNF-a 
and IL-6 levels in patients with SS correlated negatively 
with peak cortisol concentrations after hCRH, and TNF-a 
has been shown to inhibit the A C T H response of cultured 
dispersed anterior pituitary cells to C R H after 8-24 h, but 
not 4 h, incubation [40]. In addition, in critically ill 
patients with extensive burns, high cortisol concentra-
tions correlated significantly with low TNF-a levels [41]. 
These data are compatible with a direct inhibitory effect 
of chronically elevated TNF-a and/or IL-6 on the HPA 
axis in SS. Similar data from patients with rheumatoid 
arthritis are concordant with this notion [42, 43]. It is, 
therefore, possible that this phenomenon represents the 
HPA axis equivalent of the 'euthyroid sick Syndrome' in 
inflammatory states. 
The correlation between plasma cytokine and cortisol 
concentrations was weak in this study. The interaction 
between the immune System and the HPA axis in SS may 
be, therefore, more indirect. For example, both the eleva-
tion of inflammatory cytokines and the suppression of the 
H P A axis in African trypanosomiasis can be regarded as 
indices of disease activity. In this paradigm, the observed 
correlation reflects more the association with the severity 
of the underlying illness rather than a direct inhibitory 
effect of TNF-a and/or IL-6 on the H P A axis. 
High inflammatory cytokine levels in African trypa-
nosomiasis may contribute positively to the outcome of 
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infection by increasing the specific immune response 
against the parasite [44], or through direct toxicity to the 
parasite itself, as has been shown in mice experimentally 
infected with Trypanosom*! c r u c e i [45]. In patients with 
burns, the mortality rate correlates positively with endog-
enous glucocorticoids and negatively with TNF-a concen-
trations [41], Thus, the potential clinical significance of 
the H P A dysfunction observed in SS is not clear at this 
time. Only a prospective double-blind therapeutic trial of 
supplemental glucocorticoids will conclusively show 
whether the H P A axis changes observed in inflamma-
tory states are adaptive, to allow a better antiparasitic 
defense, or maladaptive, contributing to morbidity and 
mortality. 
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